Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 Inhibitor ZN-d5 in Patients With Relapsed or Refractory Light Chain (AL) Amyloidosis

Zentalis Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced that the first patient has been dosed in the potentially registrational Phase 1/2 trial of ZN-d5, the company’s oral selective BCL-2 inhibitor candidate for hematologic malignancies and related disorders, in patients with relapsed or refractory light chain (AL) amyloidosis.

“Initiating our first potentially registrational trial with ZN-d5 underscores our commitment to expanding the clinical exploration of our BCL-2 inhibitor, while also showcasing this candidate’s promise in treating this rare hematological disease,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis.